MétaCan
Menu
← Back to cohort
Record W7162010764 · doi:10.34172/ipp.2025.43986

Efficacy of metformin in the treatment of parkinsonism and depression among diabetic patients type 2

2025· article· en· W7162010764 on OpenAlexaboutno aff
Waleed S. El Nasser, Eman M. Fahmy, Ahmed M. Helmy, Mohamed Saleh, Amr Sherif Sherif Hassan, Mahmoud Abdallah Mansour Abdelrahman, Hamada H. Hassan, Basem Abd El-Hamid, Shimaa Fouad, Mai Ali Mohammad Etewa, Taha Am, Tayee Elsayed Mohamed, Alaa Abo Seif, Ahmad Mohammad Mohammad Abdella, Rashad Abd El-Nabi Atlam, Nelly Hegazy, Mohamed Ali Abbas, Mohamed Zeid, Kawashty R. Mohamed, Abdelrahman Noureldeen, Heba K. Badawy

Bibliographic record

VenueImmunopathologia Persa · 2025
Typearticle
Languageen
FieldMedicine
TopicParkinson's Disease Mechanisms and Treatments
Canadian institutionsnot available
Fundersnot available
KeywordsMetforminDepression (economics)ParkinsonismRating scaleDiseaseDiabetes mellitusPsychosocialType 2 diabetesQuality of life (healthcare)

Abstract

fetched live from OpenAlex

Introduction: Parkinson’s disease (PD) often coexists with type 2 diabetes mellitus (T2DM), which may worsen disease progression. Metformin, a common diabetes medication, showed potential benefits beyond blood sugar control. Objectives: This study examines metformin’s impact on renal function, neurological biomarkers, and clinical outcomes in patients with both PD and T2DM. Patients and Methods: This prospective case-control study involved 50 patients with both T2DM and parkinsonism, recruited from Al-Azhar university hospitals in Assiut, Egypt, between August 2024 and August 2025. Participants were divided equally into two groups; a control group receiving their standard treatment for Parkinsonism and diabetes, and a metformin-treated group receiving metformin alongside their usual therapies. Demographic data and laboratory markers were collected at baseline. Disease assessment employed standardized tools such as the unified Parkinson’s Disease Rating Scale (UPDRS) for motor function, Beck Depression Inventory (BDI) for depression severity, Hoehn and Yahr scale for disease staging, Montreal Cognitive Assessment (MoCA) for cognitive evaluation, and Parkinson’s Disease Questionnaire-39 (PDQ-39) for quality of life (QOL). All assessments were repeated after a 12-month follow-up to analyze changes relative to baseline. Results: The findings indicated that metformin treatment offers comprehensive benefits by protecting against renal function decline, influencing neurological biomarkers, and supporting multiple clinical domains in PD. It appears to mitigate disease progression, preserve cognitive function, and enhance psychosocial well-being, while having neutral effects on vitamin status and potentially positive, though non-significant, effects on inflammatory markers. Overall, metformin not only prevents typical clinical deterioration but also actively improves motor, cognitive, psychological, and quality-of-life outcomes. Conclusion: Metformin demonstrates promising multifaceted benefits in PD patients with T2DM by not only protecting renal function and preventing clinical deterioration but also actively improving motor, cognitive, psychological, and quality-of-life outcomes across multiple clinical domains, supporting its consideration as an adjunctive therapeutic strategy pending further research.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.272
Teacher spread0.260 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueImmunopathologia Persa→Same topicParkinson's Disease Mechanisms and Treatments→French-language works237,207→